Talk about a quick run after securing the cash!
On Wednesday, the pharmaceutical company Moderna announced that its chief financial officer, Jorge Gómez, left after just one day on the job, but will still be paid his full 12 months’ salary.
Prior to accepting his position at Moderna, Gomez served as Executive Vice President and Chief Financial Officer of Dentsply Sirona Inc. since August 2019.
“The announcement follows the May 10 public disclosure by Mr. Gomez’s former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting,” Moderna said in a statement from the company. company.
The internal investigation in question will determine whether the incentives that were used to help sell the dental supplier’s products to the widespread distributors were “properly accounted for,” according to CNBC.
Gomez’s departure is effective immediately, with recently retired company CFO David Meline filling the position during the interim hiring process for a new candidate.
Related: Moderna Shares Spike After Company Says Its Covid Booster Increases Antibody Levels Against Omicron
Gómez was announced as Moderna’s new CFO on April 11, a position that will take effect on May 9.
“It is a privilege for me to join an organization that is focused on developing transformative medicines to address major public health challenges around the world,” Gomez said at the time. “I look forward to working with the team on this great mission.”
Gomez will continue to receive his $700,000 salary, although he will no longer be eligible for his signing bonus or future bonuses within a year.
Denstsply board member and former Hillrom CEO John Groetelaars is currently serving as interim CEO.
The news follows Dentsply CEO Don Casey’s April 19 announcement that he had been fired from his role at the company after four years, three weeks before the company announced its less-than-stellar first-year earnings. quarter of 2022.
“The first quarter was a challenging quarter, and our financial performance and revised outlook reflect the impact of larger-than-expected macroeconomic headwinds and weaker-than-expected performance in the US,” interim CEO Groetelaars told shareholders.
Moderna, on the other hand, had a banner first quarter, tripling Covid vaccine sales to an estimated $5.9 billion in revenue, sending the stock soaring more than 7% in premarket trading on Wednesday.
Related: Moderna says its vaccine is 96% effective in adolescents